



AgiOS Announces Clinical and Preclinical Data to be Presented at AACR Annual Meeting 2014

March 31, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 31, 2014-- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that preclinical and clinical data from Agios' cancer metabolism programs will be highlighted at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-9, 2014 in San Diego, Calif.

AgiOS will host a live event with a webcast on Sunday, April 6, 2014, at 7:00 p.m. PDT (10:00 p.m. EDT) to review the clinical data from the ongoing Phase 1 study of AG-221 presented at the AACR Annual Meeting. The webcast can be accessed live or in archived form under "Events & Presentations" in the Investors and Media section of the company's website at www.agios.com.

The schedule for Agios' oral presentations and poster sessions is as follows:

Clinical Presentation

Date & Time: Sunday April 6, 2014 from 3:45p.m. – 4:05p.m. (PDT)

Session Title: Novel Immune and Targeted Therapies for Hematologic Malignancies and Solid Tumors

Session Type: Clinical Trials Symposium

Presentation Title: Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies

Presenter: Eytan Stein, M.D., Memorial Sloan-Kettering Cancer Center

Location: Ballroom 20A-C, San Diego Convention Center

Preclinical Poster and Oral Presentations

Date & Time: Sunday, April 6, 2014 from 2:00p.m. – 2:20p.m. (PDT)

Session Title: IDH Mutations in Cancer

Session Type: Major Symposium

Presentation Title: Development of mutant IDH2 inhibitors: from concept to patients

Presenter: David Schenkein, M.D., CEO, Agios Pharmaceuticals

Location: Ballroom 20 A-C, San Diego Convention Center

Date & Time: Sunday, April 6, 2014 from 3:50p.m. – 4:05p.m. (PDT)

Session Title: Cancer Metabolism: New Pathways and Progress Toward Therapy

Session Type: Minisymposium

Presentation Title: IDH2 (R140Q) knock-in mouse recapitulating human type II D-2-hydroxyglutaric aciduria

Presenter: Fang Wang, Ph.D., associate director, Agios Pharmaceuticals

Location: Room 6CF, San Diego Convention Center

Date & Time: Monday, April 7, 2014 from 8:00a.m. – 12:00p.m. (PDT)

Session Title: Human to Mouse 1

Session Type: Poster Session

Presentation Title: IDH1 mutant inhibitor induces cellular differentiation and offers a combination benefit with Ara-C in a primary human IDH1 mutant AML xenograft model

Presenter: Katharine Yen, Ph.D., director, biology, Agios Pharmaceuticals

Location: Hall A-E, Poster Section 8, San Diego Convention Center

Date and Time: Monday, April 7, 2014 from 1:00p.m. – 5:00p.m. (PDT)

Session Title: Epigenetics 3: DNA Methylation

Session Type: Poster Session

Presentation Title: IDH2 mutation induced histone and DNA hypermethylation is progressively reversed by small molecule inhibition

Presenter: Andrew Kernysky, Ph.D., senior scientist, Agios Pharmaceuticals

Location: Hall A-E, Poster Section 18, San Diego Convention Center

Date & Time: Tuesday, April 8, 2014 from 8:00a.m. – 12:00p.m. (PDT)

Session Title: Preclinical Studies in Model Organisms

Session Type: Poster Session

Presentation Title: AG-221 offers a survival advantage in a primary human IDH2 mutant AML xenograft model

Presenter: Katharine Yen, Ph.D., director, biology, Agios Pharmaceuticals

Location: Hall A-E, Poster Section 7, San Diego Convention Center

About Agios Pharmaceuticals, Inc.

AgiOS Pharmaceuticals is focused on discovering and developing novel drugs to treat cancer and inborn errors of metabolism, or IEMs, which are rare genetic metabolic diseases, through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class lead product candidates in cancer metabolism and IEMs in clinical and preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit our website at www.agios.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Agios' expectations and beliefs about the potential of its cancer metabolism programs and the benefit of its strategic plans and focus. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios' current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios' product candidates will successfully continue. There can be no guarantee that any positive developments in Agios' business will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including: Agios' results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios' ability to maintain key collaborations, such as its agreement with Celgene; and general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in Agios' Annual Report on Form 10-K for the year ended December 31, 2013, and other filings that Agios may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Source: Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals:

Glenn Goddard, SVP Finance

investors@agios.com

or

Media Contact:

Dan Budwick, 973-271-6085

dan@purecommunicationsinc.com